SCHEMBL1992198

SCHEMBL1992198

O=c1c2ncccc2[nH]c(=S)n1-c1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
LOXL3 P58215 1/20 0.48
LOXL2 Q9Y4K0 1/20 0.48
CA12 O43570 4/20 0.47
CA1 P00915 4/20 0.47
CA2 P00918 4/20 0.47
CA9 Q16790 4/20 0.47
HTT P42858 1/20 0.47
PDE7A Q13946 1/20 0.47
PDE7B Q9NP56 1/20 0.47
PKM P14618 1/20 0.45
MAPT P10636 2/20 0.45
KCNH2 Q12809 1/20 0.43
AGTR1 P30556 1/20 0.43
RXFP1 Q9HBX9 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HPGD P15428 1/20 0.40
EP300 Q09472 1/20 0.40
CREBBP Q92793 1/20 0.40
KAT2A Q92830 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2233781 0.86 LOXL3 (0.48) ALDH1A1LOXL3LOXL2CA12CA1
SCHEMBL5431810 0.83 KIF11 (0.47) ALDH1A1LOXL3LOXL2HTTPDE7A
SCHEMBL5425840 0.81 ALDH1A1 (0.59) ALDH1A1LOXL3LOXL2HTTPDE7A
SCHEMBL6283505 0.77 PDE7A (0.77) ALDH1A1CA12CA1CA2CA9
SCHEMBL5481157 0.73 MAPT (0.45) ALDH1A1LOXL3LOXL2CA12CA1
SCHEMBL11867641 0.73 PARP1 (0.47) ALDH1A1LOXL3LOXL2PDE7APDE7B
SCHEMBL5434498 0.72 MAPT (0.44) ALDH1A1CA12CA1CA2CA9
SCHEMBL5794101 0.72 ALDH1A1 (0.54) ALDH1A1LOXL3LOXL2PDE7APDE7B
SCHEMBL11556143 0.71 DAO (0.54) ALDH1A1PDE7APDE7BMAPTKCNH2
SCHEMBL30615446 0.71 DAO (0.54) ALDH1A1PDE7APDE7BMAPTKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1866310-B1 2,3-SUBSTITUTED FUSED PYRIMIDIN-4(3H)-ONES AS VR1 ANTAGONISTS MERCK SHARP & DOHME (GB) 2012-07-11 EP disclosed
US-20110152242-A1 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists MERCK SHARP & DOHME LTD. (GB) 2011-06-23 US disclosed
US-20070135454-A1 Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) BAYLISS TRACY 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152242-A1 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists NR2C2, NR3C2, NR2E3 ALDH1A1 1796/4885LOXL3 790/4885LOXL2 765/4885
US-20070135454-A1 Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) TRPV1, TRPV2, TRPV4 ALDH1A1 825/4885LOXL3 3121/4885LOXL2 2908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.